## New product application to Pharmaceutical Benefit Advisory Committee (PBAC)

4 Applicant dataile	Aughting digition to consult to
1. Applicant details	Applying clinician to complete
Name	Organisation
Role	
2. Details of product	Applying clinician to complete
Approved name	Brand name (if specific brand required)
The process manner	arana name (n opeane arana requirea,
Formulation(s) required	
(-)	
Is an existing formulation of this product already	v in the Prescribed List? Yes  No
Licensed indication(s)	
Add the second of the second o	Land on the Called and the
Will the product replace an existing product in	Insert name of existing product
the Prescribed List? Yes ⊠ No □	
If YES, which one?	
3. Intended use	Applying clinician to complete
Who is this product intended for?	7.pprymg annount to complete
Is it licensed for your intended use?	Yes □ No □
What is the usual dose and duration of	Tes 🗀 NO 🗀
treatment?	
Does this product need any monitoring?	
If so, who will do this?	
Are there any stopping criteria?	
How many people are likely to receive this	
product in Jersey?	
What is current practice for this indication?	
How does this product differ from products	
included in the Prescribed List?	
What are the advantages/disadvantages over	
existing options?	
Please describe the anticipated health	
outcomes (e.g. symptom control, cure,	
prevention)	
Are there any alternatives to treatment? Are patients at risk if this product is not used?	
Will access to the product change the patient	
pathway?	
Are specific services required to support use of	
this product? Yes □ No ⊠	
If yes, please describe	
Who will prescribe this product?	All processibore
who will prescribe this product?	All prescribers
	Specific prescribers
	(please state)
	Hospital only
	Hospital initiation/GP under shared care
	Hospital initiation/GP maintenance
	Other
	(please state)

## New product application to Pharmaceutical Benefit Advisory Committee (PBAC)

4. Evidence of safety and effectiveness	Applying clinician to complete
Is there a published appraisal/decision by	NICE □
	SMC □
	AWMSG □
Other supporting evidence (please provide references where appropriate or attach papers):	
5. Financial implications	Applying clinician to complete
What is the financial impact of using this	Overall increase in expenditure
product (full year effect) over and above	Overall decrease in expenditure $\ \square$
existing expenditure?	Cost neutral
	Don't know □
	Other $\square$
	(please state)
Estimated annual cost per patient	
Estimated number of patients to be treated	
each year	
Are there any other costs associated with	
using this product?	
6. Declaration of conflict of interests	Applying clinician to complete
Please list any:	
<ul> <li>Gifts or hospitality received from the</li> </ul>	
manufacturer of this product	
(exceeding £20) in the past year	
<ul> <li>Any payment received from the</li> </ul>	
manufacturer for presentations,	
advisory panels, consultancy work, or	
written materials	
Shares held in the manufacturer	
Sponsorship of research, members of	
staff, equipment or other materials	
funded by the manufacturer	
Any other forms of benefit or	
relationship that could be classed as a	
potential conflict of interest	

(Financial value doesn't need to be stated)